Jan 08, 2024 / 03:30PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. Happy New Year and welcome. I'm Jess Fye, senior biotech analyst at JPMorgan. We're kicking off the Healthcare Conference this morning with Incyte. I'm joined by the company's CEO, Hervé Hoppenot.
And after the presentation, we're going to host a Q&A session. You're welcome to ask questions in the room, you're welcome to submit them over the portal. You're welcome to just listen to me ask questions. But hopefully, you guys will have some of your own as well so we can make it a nice interactive Q&A session after the presentation.
So with that, welcome.
Herve Hoppenot - Incyte Corporation - CEO & Chairman
Very good. Thank you very much. Good morning. So I will speak probably for around 20 minutes. So we're speaking about where we are with Incyte. Before that, forward-looking statement, as usual.
So what I would like to do is to maybe spend a few minutes on where we are today and then give you a picture of where this
Incyte Corp at JPMorgan Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers